undamentalytics Newsletter
Sign in

Atara Biotherapeutics, Inc. income statement

In fiscal 2025, Atara Biotherapeutics, Inc. reported revenue of $121m, down 6.3% on the year before, operating income of $35.9m (a 29.7% margin) and net income of $32.7m, or $2.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6491291216
Research and development273225151374
General and administrative7251402616
Operating income−281−276−8336−14
Interest expense05543
Income before tax−228−276−8533−17
Income tax00−000
Net income−228−276−8533−17
Diluted EPS−$2.24−$65.19−$11.41$2.57−$1.17
Diluted shares (average)4m4m7m13m14m
EBITDA−275−271−7838−14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ATRA vs CGONATRA vs FATEATRA vs HCWB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atara Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atara Biotherapeutics, Inc.